Nashville-Davidson, Tennessee 2021-07-21 15:16:54 –
Nashville, Tennessee (WTVF) — Tennessee Attorney General Herbert H. Slatery is one of a bipartisan group that has announced a $ 26 billion settlement between three major pharmaceutical companies and Johnson & Johnson to end proceedings in the opioid crisis It was one.
Slatery and several state attorney generals announced the deal on Wednesday, saying the deal would be between state and local governments, major pharmaceutical companies Cardinal, McKesson, AmerisourceBergen, Johnson & Johnson. ..
What we know:
- The three distributors will pay up to $ 21 billion in total over 18 years.
- Johnson & Johnson will pay up to $ 5 billion in nine years and up to $ 3.7 billion in the first three years.
- More than two-thirds of the money needs to be spent on the treatment and prevention of opioids.
According to the announcement, the agreement “solves investigations and proceedings regarding the role of companies in the outbreak and promotion of opioid epidemics,” including approximately 4,000 proceedings filed in state and federal courts.
The agreement also requires making “significant” changes to the industry.
However, officials said ratification of the agreement was conditional on the participation of other states and local governments. The total amount of funds distributed depends on the number of participants. Authorities said the state and its local governments would receive the highest payments if each state and its local governments participated.
The state can join the agreement within 30 days, while local governments in the state can join within up to 150 days.
Mr Slateley said Tennessee would sign the agreement and encourage other states to do the same.
This agreement requires Cardinal, McKesson, and AmerisourceBergen to:
- “We have set up a centralized, independent clearinghouse to provide all three distributors and state regulators with aggregated data and analysis of drug destinations and frequencies for the systems they are currently using. Eliminate blind spots. “
- “Use a data-driven system to detect suspicious opioid orders from customers’ pharmacies.”
- “If a customer’s pharmacy ceases to receive shipments and shows signs of drug diversion, report those companies to state regulators.”
- “Please ban shipping and report suspicious opioid orders.”
- “We prohibit sales staff from influencing decisions related to identifying suspicious opioid orders.”
- “Requires corporate executives to regularly monitor diversion prevention efforts.”
Johnson & Johnson needs to do the following:
- “We will stop selling opioids for 10 years.”
- “Do not fund or subsidize third parties to promote opioids.”
- “It’s not lobbying about opioid-related activities.”
- “Share clinical trial data under the Yale University Open Data Access Project.”
According to the release, an earlier version of the deal was announced in 2019 and also included opioid maker Teva. However, officials said negotiations with Teva were underway and were no longer part of the agreement.
Drug companies, J&J reach $26B deal with states, including Tennessee, to end opioid lawsuits Source link Drug companies, J&J reach $26B deal with states, including Tennessee, to end opioid lawsuits